We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Medicaid managed care organizations, including Elevance Health, Centene and UnitedHealth Group, are working with states to secure rates that account for sicker patients.

After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other managed care insurers have largely bounced back.

New fees for claims appeals, paperwork rules for testing and time limits for certain services are novel ways to constrain spending that have providers fuming.

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price

CVS Health (NYSE:CVS), Humana (NYSE:HUM), Molina Healthcare (NYSE:MOH), and UnitedHealth Group (NYSE:UNH) saw an upswing following Elevance Health's latest quarterly results. Elevance Health, formerly known as Anthem,

The U.S. Centers for Medicare and Medicaid Services on Friday said it would not appeal a court order that it recalculate the public star ratings it gave to UnitedHealth's privately administered Medicare health insurance plans,

UnitedHealth Group said 190 million people were affected by last year's cyberattack. That's about 55% of the country's population and more than doubles the previous record.

The company said Thursday that Tim Noel will be CEO of UnitedHealthcare, replacing Brian Thompson, who was killed in New York City in December.

Flagship Harbor Advisors LLC increased its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission.

According to LCH Investments, over 200 hedge funds are Tiger Cubs, funds started by former employees of Tiger Management, the iconic hedge fund founded by Julian Robertson in 1980. After 20 mostly successful years,

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $492.5, with a high estimate of $512.00 and a low estimate of $478.00. A decline of 6.69% from the prior average price target is evident in the current average.